Q1 Earnings Estimate for Enovis Issued By Roth Capital

Enovis Co. (NYSE:ENOV - Free Report) - Investment analysts at Roth Capital issued their Q1 2025 earnings estimates for Enovis in a research report issued on Thursday, February 27th. Roth Capital analyst J. Wittes expects that the company will earn $0.73 per share for the quarter. The consensus estimate for Enovis' current full-year earnings is $2.79 per share. Roth Capital also issued estimates for Enovis' Q2 2025 earnings at $0.80 EPS, Q3 2025 earnings at $0.82 EPS and Q4 2025 earnings at $0.88 EPS.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $560.98 million during the quarter, compared to analysts' expectations of $555.14 million.

Separately, Needham & Company LLC decreased their price objective on shares of Enovis from $65.00 to $64.00 and set a "buy" rating for the company in a report on Thursday.

Enovis Stock Performance

NYSE:ENOV traded down $0.82 during mid-day trading on Monday, reaching $37.83. The company's stock had a trading volume of 1,653,938 shares, compared to its average volume of 1,013,966. The firm's fifty day moving average price is $44.72 and its two-hundred day moving average price is $44.28. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The stock has a market cap of $2.15 billion, a P/E ratio of -17.27 and a beta of 1.94. Enovis has a 12-month low of $37.60 and a 12-month high of $63.96.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Enovis by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company's stock valued at $240,731,000 after purchasing an additional 75,348 shares during the last quarter. Diamond Hill Capital Management Inc. grew its position in Enovis by 7.8% during the third quarter. Diamond Hill Capital Management Inc. now owns 3,004,694 shares of the company's stock valued at $129,352,000 after buying an additional 218,660 shares during the period. DAVENPORT & Co LLC increased its holdings in Enovis by 6.0% during the fourth quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company's stock valued at $121,181,000 after buying an additional 157,216 shares during the last quarter. Royce & Associates LP raised its position in Enovis by 2.8% in the fourth quarter. Royce & Associates LP now owns 2,470,576 shares of the company's stock worth $108,409,000 after acquiring an additional 66,891 shares during the period. Finally, State Street Corp raised its position in Enovis by 4.3% in the third quarter. State Street Corp now owns 1,647,220 shares of the company's stock worth $70,913,000 after acquiring an additional 68,190 shares during the period. Institutional investors own 98.45% of the company's stock.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.